ULTRAGENYX PHARMACEUTICAL INC. Proceeds from Sale of Intangible Assets
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Proceeds from Sale of Intangible Assets of $170.32 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2021-02-12
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from sale of intangible assets for the quarter ending 2018-12-31 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from sale of intangible assets for the quarter ending 2018-09-30 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from sale of intangible assets for the quarter ending 2018-06-30 was $40.32M.
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from sale of intangible assets for the quarter ending 2018-03-31 was $130.00M.
- ULTRAGENYX PHARMACEUTICAL INC. proceeds from sale of intangible assets for fiscal 2018 was $170.32M.
| Period end | Proceeds from Sale of Intangible Assets 0 month | Proceeds from Sale of Intangible Assets 3 month | Proceeds from Sale of Intangible Assets 6 month | Proceeds from Sale of Intangible Assets 9 month | Proceeds from Sale of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $0.00 derived: sum of 2 quarters · filed 2021-02-12 | $40.32M derived: sum of 3 quarters · filed 2021-02-12 | $170.32M 10-K · filed 2021-02-12 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $40.32M derived: sum of 2 quarters · filed 2019-11-06 | $170.32M 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $40.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $170.32M 10-Q · filed 2019-08-02 | |||
| 2018-03-31 | $130.00M 10-Q · filed 2019-05-07 | ||||
| 2018-01-10 | $130.00M 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |